New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NTE;CTIC;NIHD;IMOS;EXEL From The Last 14 Days
Check below for free stories on NTE;CTIC;NIHD;IMOS;EXEL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
06:07 EDTIMOSChipMOS to repurchase 3.3% ownership from SPIL
ChipMOS announced entry into a Share Purchase Agreement for repurchase of 1,000,000 shares or 3.3% ownership of outstanding shares of ChipMOS held by Siliconware Precision Industries. The repurchase of the shares is expected to be consummated before September 30. After the repurchase transaction, ChipMOS anticipates it will have approximately 28.8M outstanding shares, as compared to 29.8M based on number of shares outstanding as at June 30. Under the SPA executed by ChipMOS and SPIL, the purchase price of the shares will reflect a 7% discount.
August 12, 2014
16:19 EDTIMOSChipMOS to repurchase 3.3% ownership from SPIL
ChipMOS announced that its Board of Directors has approved the repurchase of 1M shares or 3.3% ownership of outstanding shares of ChipMOS held by Siliconware Precision Industries Co. Based on June 30 shareholding information, upon consummation of the proposed repurchase transaction, SPIL would hold 1,243,749 shares or 4.2% ownership of ChipMOS and 132,775,000 shares or 15.4% ownership of ChipMOS TECHNOLOGIES INC. ChipMOS anticipates that it will enter into a Share Purchase Agreement with SPIL prior to the end of August. The transaction is expected to be consummated before the end of September.
16:17 EDTIMOSChipMOS Taiwan to acquire 19% of JMC Electric Corporation
Subscribe for More Information
10:43 EDTNIHDNII Holdings downgraded to Underperform at Wells Fargo
Subscribe for More Information
10:40 EDTNIHDNII Holdings downgraded to Underperform from Market Perform at Wells Fargo
August 11, 2014
17:50 EDTNIHDNII Holdings CEO says needs to make key decisions to address liquidity
Subscribe for More Information
17:49 EDTNIHDNII Holdings reports Q2 EPS ($3.65), may not compare to consensus ($2.30)
Reports Q2 revenue $969M, consensus $948.1M.
August 8, 2014
06:09 EDTIMOSChipMOS reports July revenue up 13.2% to $64.7M
Subscribe for More Information
August 7, 2014
09:08 EDTCTICOn The Fly: Pre-market Movers
Subscribe for More Information
05:44 EDTCTICCTI BioPharma announces Pacritinib granted fast track designation by FDA
CTI BioPharma announced that pacritinib has been granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The drug candidate is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use